1. Home
  2. FSBC vs MLYS Comparison

FSBC vs MLYS Comparison

Compare FSBC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Five Star Bancorp

FSBC

Five Star Bancorp

HOLD

Current Price

$36.53

Market Cap

804.1M

Sector

Finance

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$37.07

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FSBC
MLYS
Founded
2002
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
804.1M
3.1B
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
FSBC
MLYS
Price
$36.53
$37.07
Analyst Decision
Buy
Strong Buy
Analyst Count
6
7
Target Price
$37.83
$47.33
AVG Volume (30 Days)
61.7K
1.5M
Earning Date
01-26-2026
02-11-2026
Dividend Yield
2.19%
N/A
EPS Growth
19.76
N/A
EPS
2.70
N/A
Revenue
$141,930,000.00
N/A
Revenue This Year
$34.35
N/A
Revenue Next Year
$17.79
N/A
P/E Ratio
$13.55
N/A
Revenue Growth
25.41
N/A
52 Week Low
$22.22
$8.24
52 Week High
$38.86
$47.65

Technical Indicators

Market Signals
Indicator
FSBC
MLYS
Relative Strength Index (RSI) 53.53 43.16
Support Level $35.87 $36.50
Resistance Level $38.00 $38.23
Average True Range (ATR) 1.11 1.68
MACD -0.09 0.09
Stochastic Oscillator 40.73 41.96

Price Performance

Historical Comparison
FSBC
MLYS

About FSBC Five Star Bancorp

Five Star Bancorp is a bank holding company through its subsidiary it operates in California state-chartered non-member bank. The Company provides a broad range of banking products and services to small and medium-sized businesses, professionals, and individuals. It offers loan products like commercial real estate loans, commercial loans, commercial land and construction loans, and farmland loans and offers deposit products like checking accounts, savings accounts, money market accounts, and term certificate accounts. The group has one reportable operating segment; Banking.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: